Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 2/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108101 | 0.66 | CYP3A4 (0.55) | MAPK1ALDH1A1MAPK9KMT2ACYP1A2 | |
| SCHEMBL7337339 | 0.65 | NPC1 (0.36) | ALDH1A1KMT2AHPGDKDM4EPKM | |
| SCHEMBL7344975 | 0.65 | HSP90AA1 (0.38) | MAPK1ALDH1A1PTGS2EDNRAHPGD | |
| SCHEMBL11459800 | 0.64 | MAPK9 (0.57) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL1154990 | 0.63 | MAPK9 (0.56) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL22722996 | 0.63 | MAPK9 (0.56) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL29785806 | 0.63 | MAPK9 (0.56) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL4510613 | 0.63 | MAPK9 (0.56) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL31193054 | 0.62 | EDNRA (0.64) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 | |
| SCHEMBL7333176 | 0.62 | MAPK9 (0.55) | MAPK1ALDH1A1MAPK9KMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | claimed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | MAPK1 2510/4885ALDH1A1 3140/4885MAPK9 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.